Literature DB >> 1710608

Expression of leucocyte adhesion molecules on 66 clinical neuroblastoma specimens.

M C Favrot1, V Combaret, E Goillot, E Tabone, E Bouffet, D Dolbeau, R Bouvier, C Coze, J Michon, T Philip.   

Abstract

LFA-3, ICAM-1, HLA.ABC and HLA.DR expression was analyzed on 66 neuroblastoma specimens. HLA.ABC was expressed on 26 specimens, HLA.DR on 2, LFA-3 on 20 and ICAM-1 on 10. HLA.ABC and LFA-3 were positive on ganglioneuroblastoma or ganglioneuroma, but they were negative on neuroblastoma, independently of the clinical staging; HLA.ABC and LFA-3 were induced in vivo by chemotherapy in parallel with tumoral cell differentiation, in both the primary and the metastases. The expression of ICAM-1 was restricted to 5 of the 10 low-grade stage-1 or stage-2 specimens, 1 stage-3 specimen, and the primary tumors of 2 patients with stage-4 disease, analyzed hence at diagnosis and after chemotherapy (4 specimens); metastatic cells obtained in 1 of these patients were negative. HLA.ABC and LFA-3 expressed on both mycN-negative and -positive specimens, whereas ICAM-1 was restricted to MYCN-negative specimens. LFA-3 diffusely stained partially differentiated neuroblasts, Schwann cells and ganglion cells. The expression of HLA.ABC on differentiated neuroblasts varied from one sample to another and within the same tumor; Schwann cells were strongly positive, but ganglion cells were negative. In positive samples, ICAM-1 was expressed on differentiated neuroblasts and Schwann cells, but negative on ganglion cells; however, most of the differentiated tumors were ICAM-1-negative, suggesting ICAM-1 induction by unknown local signal. The 4 markers were negative on undifferentiated neuroblasts. The distribution of these 4 markers on clinical specimens was in agreement with their reactivity on fetal tissues, as well as with results obtained on neuroblastoma cell lines before and after in vitro treatment with IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710608     DOI: 10.1002/ijc.2910480405

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Authors:  Nidale Tarek; Jean-Benoit Le Luduec; Meighan M Gallagher; Junting Zheng; Jeffrey M Venstrom; Elizabeth Chamberlain; Shakeel Modak; Glenn Heller; Bo Dupont; Nai-Kong V Cheung; Katharine C Hsu
Journal:  J Clin Invest       Date:  2012-08-06       Impact factor: 14.808

Review 2.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

3.  Cell surface expression and serum levels of intercellular adhesion molecule-1 in renal cell carcinoma.

Authors:  R Heicappell; J Podlinski; H Buszello; R Ackermann
Journal:  Urol Res       Date:  1994

4.  Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.

Authors:  P Shamamian; M Mancini; Y Kawakami; N P Restifo; S A Rosenberg; S L Topalian
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

5.  Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing.

Authors:  E Katsanis; M A Bausero; H Xu; P J Orchard; Z Xu; R S McIvor; A A Brian; B R Blazar
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.

Authors:  N K Foreman; D R Rill; E Coustan-Smith; E C Douglass; M K Brenner
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

7.  Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.

Authors:  Lotte Spel; Jaap-Jan Boelens; Dirk M van der Steen; Nina J G Blokland; Max M van Noesel; Jan J Molenaar; Mirjam H M Heemskerk; Marianne Boes; Stefan Nierkens
Journal:  Oncotarget       Date:  2015-11-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.